Abstract
Background
Circular RNAs (circRNAs) or cholesterol metabolism have been demonstrated to participate in stomach adenocarcinoma (STAD) progression. However, the relationship between circRNAs and cholesterol metabolism in STAD and its underlined mechanism remain unclear.
Methods
RNA and protein expression levels were detected by qRT-PCR and Western blot. Cell proliferation was assessed by CCK-8, EdU incorporation and colony formation assays. Total cholesterol (TC) and free cholesterol (FC) levels were measured by the corresponding kits. The relationships between circ_0000182 and miR-579-3p or squalene epoxidase (SQLE) mRNA were investigated by bioinformatics analysis, RNA-RNA pull-down, luciferase reporter and RIP assays.
Results
We found that circ_0000182 expression was significantly up-regulated in both STAD tissues and cell lines, and high circ_0000182 expression was correlated with increased tumor size. Circ_0000182 promoted cell proliferation and cholesterol synthesis of STAD cells. Accordingly, cell proliferation, cholesterol synthesis and SQLE expression were significantly inhibited by circ_0000182 knockdown in STAD cells, and these effects were partly reversed by miR-579-3p inhibition or SQLE over-expression. Furthermore, we identified that circ_0000182 acted as a competing endogenous RNA (ceRNA) by sponging miR-579-3p, thereby facilitating SQLE expression, cholesterol synthesis and cell proliferation.
Conclusion
Circ_0000182 promotes cholesterol synthesis and proliferation of STAD cells by enhancing SQLE expression via sponging miR-579-3p.
Supplementary Information
The online version contains supplementary material available at 10.1007/s12672-023-00630-5.
Keywords: STAD, Cholesterol metabolism, circ_0000182, miR-579-3p, SQLE
Introduction
According to the latest data released by the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO), stomach cancer ranks the fifth in the incidence rate and fourth in tumor related mortality rate of malignant tumors worldwide [1, 2]. The main pathological type of stomach cancer is stomach adenocarcinoma (STAD), which accounts for over 95% of all stomach cancer cases [3]. Because of the lack of specific early symptoms and diagnostic markers, most patients with STAD are diagnosed at the advanced-stages, which leads to the high mortality rate of patients with STAD [4–6]. Despite recent advances in diagnosis and treatment of patients with STAD, the overall survival rate (OSR) in the patients has not markedly elevated over the last decade [7, 8]. Therefore, the searches for specific tumor markers and effective therapeutic targets have become focuses in STAD diagnosis and treatment fields in recent years.
Abnormal tumor cholesterol metabolisms are mainly manifested by up-regulation of cholesterol synthesis, increase of cholesterol uptake, and abnormal accumulation of a large number of metabolic products, which enhance the adaptability of tumor cells to the microenvironment and promote the cell proliferation, invasion, metastasis and other malignant biological behaviors [9–12]. A report published in the “Blood” in 2022 showed that cholesterol metabolism provides indispensable cell membrane components and many important metabolic intermediates to support cell proliferation in hematopoietic malignancies [9]. Squalene epoxidase (SQLE) is a monooxygenase that catalyzes squalene to 2,3-epoxy squalene in cholesterol synthesis pathway [13–15]. Moreover, SQLE has been found to be over-expressed in breast cancer and hepatocellular carcinoma tissues, and associated with poor prognosis of patients with these tumors [13–15]. However, the role and mechanism of SQLE-mediated cholesterol synthesis in STAD progression remain further explored.
Increasing studies in recent years demonstrated that non-coding RNAs (ncRNAs), including circular RNAs (circRNAs) and microRNAs (miRNAs), may function as tumor suppressors or oncogenes in various type of tumors [16]. Furthermore, some circRNAs have been identified as key regulators in STAD progression, and may be used as tumor biomarkers for early diagnosis, therapy and prognosis of STAD [17]. As reported, circRNAs are involved in lipid metabolism, and function as crucial regulators in the occurrence and development of gestational diabetes mellitus and cardiovascular disease (CVD) [18, 19]. Furthermore, some circRNAs have been shown to participate in cholesterol metabolism by reducing cholesterol efflux from macrophages, and promoting cholesterol synthesis in aortic endothelial cells [20, 21]. However, the role and mechanism of circRNAs in tumor cholesterol metabolism still remain to be explored. Therefore, exploring the role and mechanism of circRNAs in STAD cholesterol metabolism will help clarify the relationship between cholesterol metabolism and STAD progression from the perspective of ncRNAs.
It's worth noting that circRNAs can function as competing endogenous RNAs (ceRNAs) to sponge their corresponding miRNAs and thus regulate their downstream target genes’ expressions in STAD [22]. Interestingly, our previous study demonstrated that circRNA circ_0001093 could act as a ceRNA for miR-579-3p to promote glutamine metabolism and cell proliferation of esophageal squamous cell carcinoma (ESCC) cells [23]. MiR-579-3p has been reported to be down-regulated and exert a tumor suppressor in various types of tumors, including ESCC [23], hepatocellular carcinoma [24], nasopharyngeal carcinoma [25], and pancreatic carcinoma [26]. Based on GEPIA database (http://gepia.cancer-pku.cn/), SQLE was found to be highly expressed in STAD tissues. MiRNA target prediction databases TargetScanHuman (https://www.targetscan.org/) and miRDB (https://mirdb.org/) indicated SQLE mRNA possessed a miR-579-3p (hsa-miR-579-3p) targeting binding sequence. And then circRNA target prediction databases Circular RNA Interactome (https://circinteractome.nia.nih.gov/) and circbank (http://www.circbank.cn/) indicated miR-579-3p possessed a circ_0000182 (hsa_circ_0000182) targeting binding sequence. Therefore, it is reasonable to speculate that circ_0000182/miR-579-3p/SQLE axis may participate in regulating STAD progression.
Circ_0000182 is a newly discovered circRNA with a spliced sequence length of 458 bp, and the coding gene is located at chr1:213037066–213058738 (https://circinteractome.irp.nia.nih.gov/). However, so far, the role of circ_0000182 in tumors has not been reported. Through bioinformatics analysis and experimental validation, we found that circ_0000182 could modulate the expression of SQLE through ceRNA mechanism, and play a role in regulating cholesterol metabolism in STAD. Thus, exploring its role and mechanism of circ_0000182 in STAD progression may provide novel biomarkers and/or targets for diagnosis and treatment of STAD.
Materials and methods
Clinical samples
Clinical studies were approved by the Ethics Committee of Taizhou University Hospital. Forty patients with STAD at Taizhou University Hospital were recruited and signed informed consent voluntarily. Major inclusion criteria were: (1) Patients diagnosed with STAD by two senior pathologists; (2) Patients provided informed consents. Major exclusion criteria were: (1) Patients received chemotherapy or other therapies before the surgery; (2) Patients with a history of other malignant diseases within 5 years. A total of primary STAD and matched normal tissue specimens (Taizhou cohort 1 N = 40 for qPCR and Western blot; Taizhou cohort 1 N = 78 for IHC) were obtained from the Taizhou Central Hospital (Taizhou University Hospital) from 2016 to 2020. STAD tissue specimens and their matched non-tumor tissue specimens were immediately frozen in liquid nitrogen.
Cell culture
Human gastric mucosal epithelial cells (GES-1) and human STAD cell lines (MKN-28, AGS, SGC-7901 and BGC-823) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). All the cells were incubated in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) mixed with 10% fetal bovine serum (FBS, Gibco) in an atmosphere at 37 ℃ with 5% CO2.
qRT-PCR
Trizol reagent (Invitrogen, Carlsbad, CA, USA) was used for total RNA extractions from STAD tissue specimens and in vitro cultivated cells. Following the determination of RNA concentration and purity, the total RNA was converted to cDNA using the PrimeScript 1st Strand cDNA Synthesis Kit (Takara, Dalian, China) or the Mir-X™ miRNA First-Strand Synthesis Kit (TaKaRa) according to the manufacturer’s requirements, respectively. The obtained cDNA was then analyzed by qRT-PCR using SYBR premix Ex Taq™ II kit (Takara) according to the manufacturer’s requirements. GAPDH and U6 were used as internal controls for mRNAs and miR‐579-3p, respectively. All primer sequences designed using Primer-Blast online tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) or as described previously [25, 27] are listed in Table 1. Finally, the relative RNA expression levels were evaluated using the 2−ΔΔCt method.
Table 1.
Name | Primer sequence |
---|---|
circ_0000182 |
Forward: 5′-TGCTGGAAGGATTGGGCTAA-3′ Reverse: 5′-CAAGCACCCCTCCAGTAACA-3′ |
miR-579-3p | Forward:5′-GCGCTTCATTTGGTATAAACC-3′ |
Reverse:5′-GGCAATTGCACTGGATG-3′ | |
SQLE |
Forward: 5′-TGGTTACATGATTCATGATC-3′ Reverse: 5′-TACTGAACTCCCATCACAAC-3′ |
GAPDH |
Forward: 5′-GCACCGTCAAGGCTGAGAAC-3′ Reverse: 5′-GCCTTCTCCATGGTGGTGAA-3′ |
U6 |
Forward: 5′-GCTTCGGCAGCACATATACTAAAAT-3′ Reverse: 5′-CGCTTCACGAATTTGCGTGTCAT-3′ |
RNase R digestion assay
To identify the character of circ_0000182, 5 μg total RNA isolated from STAD cells was subjected for RNase R (Tiangen Biochemical, China) for 30 min at 37 ℃. Subsequently, the obtained total RNA was analysed by qRT-PCR.
CCK-8 assay
The CCK-8 kit (Abcam, Cambridge, MA, USA) was used following the manufacturer’s introductions. In detail, STAD cells (3 × 103/100 μl/well) were seeded into the 96-well plates, and six replicates for each sample were set at the same time. Different intervention factors and time were applied to the STAD cells, and then 10 μl of CCK-8 solution which was evenly mixed in 100 μl of fresh medium were added into each well. Plates were incubated for 2 h at 37 ℃, and the absorbance was recorded at 450 nm with a microplate reader (Bio-Rad, Hercules, CA, USA).
Colony formation assay
STAD cells were plated at a density of 40 cells/cm2 in 6-well plates and incubated for 14 days. The medium were changed every 3 days. Subsequently, the resulting cell colonies were washed thrice with PBS, fixed with 4% paraformaldehyde for 10 min at 4 ℃, and stained with 0.1% crystal violet for 30 min at room temperature. Visible colonies (> 50 cells/colony) were manually counted.
EdU incorporation assay
The cell proliferation was detected using a BeyoClick™ EDU Cell Proliferation Kit with 3,3',5,5'-Tetramethylbenzidine (TMB) (Beyotime Biotechnology, Shanghai, China) according to the manufacturer’s instructions. In brief, STAD cells were seeded in 96-well plates at 5 × 103 cells per well. 5-ethynyl-2'-deoxyuridine (EdU) was incorporated into the DNA synthesis of cells. Under the catalysis of copper ion, EdU was labeled with biotin, and then HRP streptavidin was added to combine with biotin, and the color was determined by TMB chromogenic solution. The plates were read with a single wavelength of 630 nm using a microplate reader (Thermo Scientific, Rochester, NY, USA).
Total cholesterol (TC) and free cholesterol (FC) assays
The amounts of TC and FC were assessed with a TC quantification detection kit (Solarbio, Beijing, China) and a FC quantification detection kit (Solarbio) following the manufacturers’ instructions, respectively. In brief, the culture medium was discarded from 12-well plates and the cells were washed twice with PBS. 0.5 ml cell lysate was added to every 5 × 106 cells, and 0.5 ml distilled water was added after severe oscillation. After 12,000 × g centrifuged for 10 min at 4 ℃, the lower supernatant was collected. After adding the trichloroacetic acid to precipitate cells, the cells were broken up by ultrasound after adding equal volume of chloroform: methanol mixed solution (2:1). After centrifugation, the supernatant was collected and the contents of TC and FC were determined by enzyme colorimetry according to the instructions of the kits. Next, the remaining cell sediment was dissolved in 0.1 mol/L NaOH, and the intracellular protein content was detected by Bradford method. The intracellular cholesterol content is expressed in μg/mg cell protein.
Western blotting
The whole extracts from BGC-823 cells were prepared using RIPA buffer (Beyotime, Shanghai, China), and the total protein concentrations in the extracts were quantified using a BCA Protein Assay kit (Pierce Rockford, IL, USA) following the manufacturers’ introductions. The protein samples were subjected to sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred from the SDS-PAGE gel to the PVDF membrane (Millipore, MA, USA), which was then incubated overnight at 4 ℃ with primary antibody. The primary antibodies against SQLE (1:1000, catalog no.ab189773; Abcam, Cambridge, MA, USA) and GAPDH (1:1000, catalog no. ab181602; Abcam) were used. GAPDH was used as an internal control. The next day, the PVDF membrane was washed and then incubated with a specific secondary antibody conjugated to horseradish peroxidase for 2 h at room temperature. Finally, immunoreactivity was detected by an enhanced chemiluminescence system kit (Pierce, Waltham, MA, USA) and photographed by an LAS-4000 imaging system (Fujifilm Holdings Corporation, Tokyo, Japan).
Tissue array
Analysis of SQLE protein expression by immunohistochemistry (IHC) was done on a STAD tissue array (Shanghai Outdo Biotech, Shanghai, China), containing 78 pairs of samples from STAD tissues and adjacent non-tumor tissues, using an automated immunostainer (Benchmark XT; Roche, Basel, Switzerland). Tumor staging was judged by two senior pathologists using the tumor-node-metastasis (TNM) classification system according to the protocol of International Union Against Cancer (UICC). The DAKO EnVision system (DAKO, Carpinteria, CA, USA) was used to analyze the immunohistochemical expression of SQLE protein. All images (× 200) were photographed and analyzed with an Aperio scanner (Aperio Technologies, Vista, CA, USA).
RNA pull-down assay
48 h after transfection with biotinylated wild-type (WT) miR-579-3p (Bio-miR-579-3p-WT), mutant (MT) miR-579-3p (Bio-miR-579-3p-MT) or antagonistic miR-579-3p probe (GenePharma, Shanghai, China), the STAD cells were collected and lysed in specific lysis buffer (Ambion, Austin, TX, USA) for 10 min, and then mixed with M-280 streptavidin magnetic beads (Sigma-Aldrich, St. Louis, MO, USA) at 4 ℃ for 3 h. Trizol reagent (Invitrogen) was used to elute and purify the interacting RNA complex, and qPCR was used to detect the expression of circ_0000182 in the RNA complex.
Luciferase reporter assay
In order to generate wild-type miR-579-3p reporter gene (miR-579-3p-WT) and SQLE reporter gene (SQLE-WT), the partial sequences of miR-579-3p and SQLE 3′-untranslated region (UTR), which separately contained the putative circ_0000182 and miR-579-3p binding sites, were amplified by PCR and then cloned into the pmirGLO luciferase vectors (Promega, Madison, WI, USA), respectively. Mutant miR-579-3p (circ_0000182 target site-mutation miR-579-3p, miR-579-3p-MUT) reporter gene and mutant SQLE (miR-579-3p target site-mutation SQLE 3′-UTR, SQLE-MUT) reporter gene were produced by GeneArt™ Site-Directed Mutagenesis System (Thermo Fisher Scientific, Waltham, MA, USA). All constructs were verified by DNA sequencing. Subsequently, the luciferase reporter genes, sh-circ_0000182 or sh-NC, and miR-579-3p mimic or control mimic were co-transfected into STAD cells, respectively. After 48 h, the cells were harvested, and the luciferase activity was detected using the dual luciferase reporter system (Promega).
RIP assay
After transfection of STAD cells with miR-579-3p mimic or control mimic (Promega, Madison, WI, USA), RIP detection was performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, MA, USA) according to the manufacturer's instructions. In brief, the collected cells were lysed in RIP lysis buffer. Then, the cell lysis was incubated with RIP buffer containing magnetic beads linked to Argonaute2 (AGO2) antibody or IgG antibody at 4 ℃, using IgG as a negative control, the RNA complex was extracted after elution with protease K, and qPCR was used to detect the expression of circ_0000182 in the RNA complex.
Statistical analysis
Data were analyzed using SPSS 25.0 software (SPSS Inc., IL, USA) and presented as mean ± standard deviation (SD). Comparisons of two groups were analyzed by Student's t tests, and comparisons of three or more groups comparisons were analyzed by ANOVA (Tukey's post hoc test). The correlations between circ_0000182 expression and clinical parameters were analyzed using the χ2-test. The correlations between circ_0000182, miR-579-3p and SQLE mRNA expressions in STAD tissues were determined by Pearson’s correlation analysis. P values < 0.05 were considered to be statistically significant.
Results
SQLE and circ_0000182 expressions are both up-modulated, and miR-579-3p expression is down-modulated in STAD tissues
To assess the role of SQLE expression in STAD tissues, we acquired its expression profile in 408 STAD tissue samples and 211 normal tissue samples from GEPIA database (http://gepia.cancer-pku.cn/index.html), and found that the mRNA of SQLE was significantly up-modulated in STAD tissues compared with normal tissues (Fig. 1A). Subsequently, we validated SQLE mRNA expression in tissue samples from 40 patients with STAD, and confirmed that SQLE mRNA level was significantly higher in the STAD tissues compared with adjacent non-tumor tissues (Fig. 1B). Further, the results in tissue arrays from 78 STAD patients manifested that the high expression rate of SQLE protein in STAD tissues was 57.69% (45/78), the high expression rate of SQLE protein in adjacent non-tumor tissues was 35.90% (28/78), and there was significant difference between the two groups (P < 0.01) (Table 2). SQLE protein was mainly expressed in the cytoplasm and nucleus of STAD tissues, while a small amount was expressed in the cytoplasm and nucleus of adjacent non-tumor tissues (Fig. 1C). Thus, our data demonstrated that SQLE expression was up-regulated in STAD tissues (Figure S1).
Table 2.
Groups | High expression of SQLE protein | Low expression SQLE protein | χ2 value | P value |
---|---|---|---|---|
STAD tissues | 45 | 33 | ||
Adjacent non-tumor tissues | 28 | 50 | 7.440832 | 0.006376** |
**P < 0.01
The miRDB database (http://mirdb.org/) was used to predict the miRNAs that bind to the 3'-UTR of SQLE mRNA, and hsa-miR-579-3p (miR-579-3p) with the highest context score (Target Score = 96) was selected as a miRNA that might bind to the 3'-UTR of SQLE mRNA (Table S1), and the TargetScanHuman database (http://www.targetscan.org/) further verified the binding of miR-579-3p to SQLE mRNA 3'-UTR, and the predicted scores (the context + + score percentile) for the two sites of miR-579-3p binding to SQLE mRNA 3'-UTR both are 93 (Table S2). The circRNAs binding to miR-579-3p were comprehensively analyzed and predicted by Circular RNA Interactome database (https://circinteractome.nia.nih.gov/), hsa_circ_0000182 (circ_0000182) with a context score ≥ 99 was selected as a circRNA that binds to miR-579-3p, and while the binding of circ_0000182 to miR-579-3p sequence was manifested in Table S3. Through GEPIA database analysis, we found that the parental gene of circ_0000182, FLVCR1 (feline leukemia virus subgroup C cellular receptor 1), was significantly highly expressed in STAD tissues (Fig. 1D), which indirectly suggested that circ_0000182 is highly expressed in STAD tissues (Figure S2).
Next, we tested its RNA levels in 40 STAD specimens relative to 40 adjacent non-tumor tissues using qRT-PCR, and found that circ_0000182 expression was considerably increased in the STAD tissues when compared to their matched adjacent non-tumor tissues (Fig. 1E). MiR-579-3p mRNA expression in the 40 specimens of STAD tissues was also examined by qRT-PCR assay, and the result demonstrated that, compared with that found in the paired adjacent non-tumor tissues, miR-579-3p expression level was significantly lower in STAD tissues (Fig. 1F). We further found that circ_0000182 expression level was significantly related to tumor size, but there was no relationship between circ_0000182 expression level with gender, age, HP infection, lymph node metastasis or TNM stage (Table 3). In STAD tissues, circ_0000182 expression manifested a negative and significant correlation with miR-579-3p (r = − 0.628, P < 0.001; Fig. 1G), and a positive and significant correlation with SQLE mRNA (r = 0.706, P < 0.001; Fig. 1H). In addition, there was a negative and significant correlation between the miR-579-3p and SQLE mRNA expressions in STAD tissues (r = − 0.687, P < 0.001; Fig. 1I). Taken together, our data suggest that circ_0000182 negatively regulates miR-579-3p expression and positively regulate SQLE expression in STAD tissues, and meanwhile miR-579-3p might negatively regulate SQLE expression in the tissues.
Table 3.
Characteristics | Case | Circ_0000182 expression | χ2 | P-value | |
---|---|---|---|---|---|
High | Low | ||||
Gender | 0.416667 | 0.518605 | |||
Male | 24 | 13 | 11 | ||
Female | 16 | 7 | 9 | ||
Age (years) | 0.102302 | 0.749085 | |||
≤ 65 | 17 | 8 | 9 | ||
> 65 | 23 | 12 | 11 | ||
Lymph node metastasis | 2.666667 | 0.102470 | |||
Negative | 15 | 5 | 10 | ||
Positive | 25 | 15 | 10 | ||
TNM stage | 3.636364 | 0.056530 | |||
I, II | 18 | 6 | 12 | ||
III | 22 | 14 | 8 | ||
Tumor size | 4.912281 | 0.026666* | |||
≤ 5 cm | 19 | 6 | 13 | ||
> 5 cm | 21 | 14 | 7 | ||
HP infection | 0.439560 | 0.507335 | |||
Negative | 14 | 6 | 8 | ||
Positive | 26 | 14 | 12 |
*P < 0.05
Circ_0000182 is up-regulated in STAD cell lines, and promotes cell proliferation of STAD cells
We analyzed the circ_0000182 expression level among STAD cell lines (MKN-28, AGS, SGC-7901 and BGC-823) and human gastric mucosal epithelial cells (GES-1) via qRT-PCR. The results revealed that circ_0000182 expression was significantly up-modulated in the four STAD cell lines compared with GES-1 cells (Fig. 2A). In the four STAD cell lines, BGC-823 and AGS cells manifested the relative high levels of circ_0000182 expression, and meanwhile MKN-28 cells manifested the relative low level of circ_0000182 expression (Fig. 2A). Therefore, the three cell lines were used for the next loss- and gain-of-function experiments. Then, RNase R degradation assay was used to confirm the stable existence of circ_0000182 in STAD cells. The data demonstrated that the circ_0000182 resisted to the RNase R treatment, while the linear RNA (FLVCR1 mRNA) was degraded in both BGC-823 (Fig. 2B) and AGS cells (Fig. 2C).
To further explore the function of circ_0000182 in STAD progression, the short hairpin RNAs (shRNAs) specific against circ_0000182 (sh-circ_0000182#1, sh-circ_0000182#2) and circ_0000182 over-expressing plasmid (p-circ_0000182) were designed and constructed, and circ_0000182 knockdown and circ_0000182 over-expression cell lines were established, respectively. The knockdown or over-expression of circ_0000182 efficiency was evaluated by qRT-PCR (Fig. 2D-F). The CCK-8 assay showed that knockdown of circ_0000182 significantly inhibited the cell proliferation of BGC-823 and AGS cells (Fig. 2G, H), and meanwhile over-expression of circ_0000182 significantly promoted the cell proliferation of MKN-28 cells (Fig. 2I). Similar results were observed in EdU incorporation and colony formation assays. The results of the EdU incorporation assay indicated that compared to the control cells, knockdown of circ_0000182 significantly inhibited the proliferation of BGC-823 and AGS cells, whereas over-expression of circ_0000182 promoted the cell proliferation of MKN-28 cells (Fig. 2J–L). Consistently, compared to the control cells, circ_0000182 over-expression significantly inhibited the clonogenic abilities of BGC-823 cells, while circ_0000182 over-expression manifested the opposite effects in MKN-28 cells (Fig. 2M–P). Taken together, our data demonstrated that circ_0000182 promoted the cell proliferation of STAD cells.
Circ_000182 participates in promoting cholesterol synthesis in STAD cells
To assess whether circ_0000182 contributes to the promotion of cholesterol synthesis in STAD cells, we used the corresponding test kits to detect total cholesterol (TC) and free cholesterol (FC) levels in circ_0000182-knockdown and circ_0000182-over-expression STAD cells. The results demonstrated that circ_0000182 knockdown significantly decreased TC (Fig. 3A and 3C) and FC (Fig. 3B and 3D) levels in BGC-823 and AGS cells. Meanwhile, circ_0000182 over-expression significantly increased TC (Fig. 3E) and FC (Fig. 3F) levels in MKN-28 cells. Taken together, our data indicated that circ_0000182 contributed to the promotion of cholesterol synthesis in STAD cells.
Circ_0000182 acts as a ceRNA by sponging miR-579-3p in STAD cells
Our present bioinformatics analysis by the Circular RNA Interactome database (https://circinteractome.nia.nih.gov/) manifested that circ_0000182 might share the binding sites with miR-579-3p (Fig. 4A). To investigate the binding capability of circ_0000182 and miR-579-3p, a luciferase reporter assay and a RNA-RNA pull-down assay were conducted. The result of luciferase reporter assay manifested that the luciferase activity of wild-type miR-579-3p was enhanced by circ_0000182 knockdown in BGC-823 and AGS cells, while that of mutant miR-579-3p was not significantly changed in the cells (Fig. 4B, C), and the result of RNA-RNA pull-down assay revealed that wild-type miR-579-3p was captured by circ_0000182 in BGC-823 and AGS cells (Fig. 4D, E). In addition, the RIP assay result presented that both circ_0000182 and miR-579-3p were markedly enriched in anti-Ago2 immunoprecipitation compared with the control mimic group, indicating that circ_0000182 and miR-579-3p coexisted in RNA Induced Silencing Complex (RISC) (Fig. 4F, G).
To further investigate whether circ_0000182 could modulate miR-579-3p expression in STAD cells, we measured the miR-579-3p expression in circ_0000182-knockdown BGC-823 and AGS cells and circ_0000182-overexpression MKN-28 and SGC-7901 cells, and found that knockdown of circ_0000182 significantly promoted miR-579-3p expression in BGC-823 and AGS cells (Fig. 4H, I), and meanwhile over-expression of circ_0000182 significantly inhibited miR-579-3p expression in MKN-28 and SGC-7901 cells (Fig. 4J, K). Taken together, these data confirmed that circ_0000182 targeted miR-579-3p in STAD cells by directly binding miR-579-3p.
miR-579-3p targets SQLE in STAD cells
Our present bioinformatics analysis by the TargetScan database (https://www.targetscan.org/vert_80/) manifested that miR-579-3p might share the binding sites with SQLE mRNA 3'-UTR (Fig. 5A). A dual luciferase reporter assay was used to confirm that miR-579-3p directly targets SQLE mRNA 3'-UTR in BGC-823 and AGS cells, and demonstrated that the miR-579-3p mimic led to a significant decrease in the luciferase activity of the wild type of SQLE mRNA 3'-UTR (SQLE-WT) reporter in BGC-823 and AGS cells, but not in the mutant 3'-UTR of SQLE (SQLE-MUT) reporter in the cells (Fig. 5B, C). Furthermore, qRT-PCR analysis demonstrated that up-regulation of miR-579-3p expression via miR-579-3p mimic (Fig. 5D, E) significantly decreased SQLE mRNA expression in BGC-823 and AGS cells (Fig. 5F,G). And meanwhile down-regulation of miR-579-3p expression via miR-579-3p inhibitor (Fig. 5H, I) significantly increased SQLE mRNA expression in MKN-28 and SGC-7901 cells (Fig. 5J, K). Taken together, these data confirmed that miR-579-3p targeted SQLE in STAD cells by directly targeting SQLE mRNA 3'-UTR.
Knockdown of circ_0000182 inhibits cell proliferation and cholesterol synthesis of BGC-823 cells via miR-579-3p/SQLE axis
Rescue assays were carried out by decreasing miR-579-3p expression via miR-579-3p inhibitor or increasing SQLE expression via p-SQLE in BGC-823 cells with circ_0000182 knockdown via sh-circ_0000182#1. The results of CCK-8, EdU incorporation and colony formation assays manifested that the cell proliferation of BGC-823 cells was significantly inhibited by circ_0000182 knockdown, and then it was partially reversed by miR-579-3p inhibition or SQLE over-expression (Fig. 6A–D). Meanwhile, the TC and FC levels in BGC-823 cells were significantly decreased by circ_0000182 knockdown, and then they were partially reversed by miR-579-3p inhibition or SQLE over-expression (Fig. 6E, F). The data indicated that miR-579-3p inhibition or SQLE over-expression in BGC-823 cells partially recovered cell proliferation and cholesterol synthesis, which was inhibited by circ_0000182 knockdown. Consistently, SQLE mRNA and protein expression levels were significantly decreased by circ_0000182 knockdown, and then they were partially reversed by miR-579-3p inhibition or SQLE over-expression (Fig. 6G, H). The data indicated that miR-579-3p inhibition or SQLE over-expression in BGC-823 cells partially recovered SQLE mRNA and protein expressions, which were inhibited by circ_0000182 knockdown. Taken together, these data suggest that circ_0000182 promotes cell proliferation and cholesterol synthesis of BGC-823 cells via miR-579-3p/SQLE axis.
Discussion
Currently, although a number of circRNAs, functioning as oncogenes or tumor suppressors, have been reported to be involved in STAD progression [28–31], no studies have so far addressed circ_0000182’s role in STAD. Furthermore, there has been a few recent studies presenting that circRNAs have a strong ability to participate in regulating cholesterol metabolism in non-tumor cells, such as macrophages and aortic endothelial cells [20, 21]. However, there are few studies on circRNAs in cholesterol metabolism of tumors. In this study, we observed that circ_0000182 was increased in STAD. Furthermore, our present data validated the promotive role of circ_0000182 on cholesterol synthesis and proliferation in STAD cells. These findings were announced to be the first-hand document that the oncogenic factor of circ_0000182 in STAD provides a new perspective regarding tumor diagnosis and treatment.
Abnormal activation of cholesterol metabolism is now recognized as the prominent hallmark of human tumors, including STAD [9–12]. Interestingly, SQLE, a key rate-limiting enzyme in cholesterol synthesis, has long been considered a proto-oncogene because of its high copy number amplification and driving abnormal cholesterol metabolism in various type of tumors [32–35]. Recently, highly expressed SQLE has been shown to promote the cell proliferation of colorectal cancer (CRC) [35], prostate cancer (PCa) [36] and small cell lung cancer (SCLC) [37]. Similar to these former reports, our data displayed that SQLE expression was apparently elevated in STAD tissues, and over-expressed SQLE promoted cholesterol synthesis and proliferation in STAD cells, suggesting that SQLE functions as an oncogene in STAD, and SQLE-mediated cholesterol metabolism is involved in STAD progression. Furthermore, an animal study illustrated that SQLE inhibition with NB-598 in SCLC cells decreased cholesterol synthesis, and restrained the tumor growth in vivo [37]. Therefore, targeting SQLE-mediated cholesterol synthesis may be an effective strategy for controlling the occurrence and development of tumors. Here, we further found that circ_0000182 knockdown inhibited SQLE expression, cholesterol synthesis and proliferation, and meanwhile SQLE over-expression partly reversed the inhibitory effects of circ_0000182 knockdown. Therefore, these results suggest that circ_0000182 exerts an oncogene effect by up-regulating SQLE expression, and is a potential diagnostic marker and therapeutic target for STAD diagnosis and treatment.
It has been revealed that miRNAs are involved in the occurrence and development of STAD [38]. Interestingly, SQLE was found to be a target of miR-205 in PCa, and SQLE expression was negatively regulated by over-expressed miR-205 in PCa cells [36]. Furthermore, miRNAs has been identified to accomplish their biological functions by directly binding to the 3′-UTR of downstream target mRNAs [39]. Here, we found that miR-579-3p expression had a negative correlation with SQLE mRNA expression in STAD tissues, and over-expressed miR-579-3p inhibited SQLE mRNA expression in STAD cells. Furthermore, we confirmed that SQLE mRNA 3′-UTR contained a binding site for miR-579-3p in STAD cells. These results suggest that miR-579-3p down-regulates SQLE expression in STAD cells by directly targeting SQLE mRNA 3′-UTR. Subsequently, through bioinformatics analysis and experimental validation, we found that circ_0000182, a newly discovered circRNA, had a targeted binding site with miR-579-3p in STAD. Some circRNAs are abundant in STAD and have been proved to exert vital roles in STAD progression [17]. Furthermore, circRNAs were reported to participate in regulation of cholesterol metabolism by reducing cholesterol efflux from macrophages and promoting cholesterol synthesis in aortic endothelial cells [20, 21]. Here, we confirmed circular characteristics of circ_0000182 and elevated circ_0000182 expression in STAD. And we further found that over-expressed circ_0000182 promoted cholesterol synthesis and proliferation in STAD cells. Based on these evidences, we confirmed that circ_0000182 functioned as an oncogene by participating in regulation of cholesterol synthesis in STAD.
CeRNA networks based on circRNAs have an impact on the occurrence and development of gastrointestinal cancers [40]. Furthermore, it has been found that circRNAs acted as ceRNAs for miRNAs to regulate proliferation of STAD cells [28, 31]. Interestingly, lncRNA‐TTN‐AS1 was found to act as a ceRNA for miR‐133b to regulate the expression of SQLE in pancreatic cancer cells [41]. Here, we demonstrated that over-expressed circ_0000182 down-regulated miR-579-3p expression and up-regulated SQLE expression in STAD, and confirmed that miR-579-3p directly interacted with circ_0000182 or SQLE mRNA 3'-UTR in STAD cells. Furthermore, we subsequently investigated the relationship between circ_0000182 and cholesterol metabolism, and found that circ_0000182 participated in promoting cholesterol synthesis and proliferation in STAD. Combined with the regulatory relationship between miR-579-3p and SQLE and the adsorption relationship between circ_0000182 and miR-579-3p, these results suggest that circ_0000182 acts as a ceRNA for miR‐579-3p to up-regulate SQLE expression, resulting in promoted cholesterol synthesis and proliferation in STAD cells (Fig. 7).
Conclusion
In summary, we demonstrated that circ_0000182 acted as tumor promotion factor in STAD, and served as a ceRNA to counteract miR-579-3p-mediated SQLE suppression, thus promoting cholesterol synthesis and proliferation in STAD. Our present study not only identifies circ_0000182, a newly discovered circRNA, in STAD and its roles in STAD progression and cholesterol metabolism, but also provides a potential diagnostic marker and therapeutic target for STAD.
Supplementary Information
Acknowledgements
Not applicable.
Abbreviations
- circRNA
Circular RNA
- STAD
Stomach adenocarcinoma
- SQLE
Squalene epoxidase
- miR-579-3p
Has-miR-579-3p
- circ_0000182
Hsa_circ_0000182
- qRT-PCR
Quantitative real-time PCR
- CCK-8
Cell counting kit-8
- RIP
RNA immunoprecipitation
- IHC
Immunohistochemistry
- FLVCR1
Feline leukemia virus subgroup C cellular receptor 1
- ceRNA
Competing endogenous RNA
- IARC
International agency for research on cancer
- WHO
World health organization
- ESCC
Esophageal squamous cell carcinoma
- CRC
Colorectal cancer
- SCLC
Small cell lung cancer
- GEPIA
Gene expression profiling interactive analysis
- RISC
RNA induced silencing complex
- TC
Total cholesterol
- FC
Free cholesterol
- miRNA
MicroRNA
- non-coding RNA
NcRNAs
- OSR
Overall survival rate
- CVD
Cardiovascular disease
- shRNA
Short hairpin RNA
- UTR
Untranslated region
- FBS
Fetal bovine serum
- TNM
Tumor-node-metastasis
- PCa
Prostate cancer
- APOA1
Apolipoprotein A1
- HDL-C
High-density lipoprotein cholesterol
Author contributions
CJQ and YXZ drafted the manuscript, and contributed to the analysis and interpretation of data. LKW, YCW and XST contributed in the data collection. JY and XST conceived and designed the experiments. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.
Funding
This research was supported by the Zhejiang Provincial Natural Science Foundation of China (No.LTGY23H200001), the Zhejiang Provincial Public Welfare Technology Application Research Project of China (No.LGF22H160015), the National Natural Science Foundation of China (No.81902138), the National College Students' Innovation and Entrepreneurship Training Program of China (No.202210350057), the Science and Technology Project of Taizhou City (No.22ywa59; No.21ywb74),and the College Students' Science and Technology Innovation of Taizhou City (No.202209).
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.
Declarations
Ethics approval and informed consent
All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of the Taizhou Central Hospital (Taizhou University Hospital) (approval no. 2021-SC-008). Informed consent was obtained from all individual participants included in the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Cui-juan Qian and Yu-xin Zhou contributed equally to this work
Contributor Information
Xiao-sheng Teng, Email: txiaosheng168@163.com.
Jun Yao, Email: yaojuntzu@yeah.net.
References
- 1.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654. [DOI] [PubMed] [Google Scholar]
- 2.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
- 3.Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008. [DOI] [PubMed] [Google Scholar]
- 4.Loizides S, Papamichael D. Considerations and challenges in the management of the older patients with gastric cancer. Cancers (Basel) 2022;14:1587. doi: 10.3390/cancers14061587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Abyadeh M, Meyfour A, Gupta V, Zabet Moghaddam M, Fitzhenry MJ, Shahbazian S, et al. Recent advances of functional proteomics in gastrointestinal cancers-a path towards the identification of candidate diagnostic, prognostic, and therapeutic molecular biomarkers. Int J Mol Sci. 2020;21:8532. doi: 10.3390/ijms21228532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Dhakras P, Uboha N, Horner V, Reinig E, Matkowskyj KA. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. Transl Gastroenterol Hepatol. 2020;5:55. doi: 10.21037/tgh.2020.01.08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39:1179–1203. doi: 10.1007/s10555-020-09925-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res. 2018;7: F1000 Faculty Rev-1365. 10.12688/f1000research.15133.1. [DOI] [PMC free article] [PubMed]
- 9.Brendolan A, Russo V. Targeting cholesterol homeostasis in hematopoietic malignancies. Blood. 2022;139(2):165–176. doi: 10.1182/blood.2021012788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132–141. doi: 10.1038/s42255-020-0174-0. [DOI] [PubMed] [Google Scholar]
- 11.Peng L, Yan Q, Chen Z, Hu Y, Sun Y, Miao Y, et al. Research progress on the role of cholesterol in hepatocellular carcinoma. Eur J Pharmacol. 2023;938:175410. doi: 10.1016/j.ejphar.2022.175410. [DOI] [PubMed] [Google Scholar]
- 12.Meng Y, Wang Q, Lyu Z. Cholesterol metabolism and tumor. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50:23–31. English. 10.3724/zdxbyxb-2021-0033. [DOI] [PMC free article] [PubMed]
- 13.Brown DN, Caffa I, Cirmena G, Piras D, Garuti A, Gallo M, et al. Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. Sci Rep. 2016;6:19435. doi: 10.1038/srep19435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cirmena G, Franceschelli P, Isnaldi E, Ferrando L, De Mariano M, Ballestrero A, et al. Squalene epoxidase as a promising metabolic target in cancer treatment. Cancer Lett. 2018;425:13–20. doi: 10.1016/j.canlet.2018.03.034. [DOI] [PubMed] [Google Scholar]
- 15.Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10:eaap9840. doi: 10.1126/scitranslmed.aap9840. [DOI] [PubMed] [Google Scholar]
- 16.Torsin LI, Petrescu GED, Sabo AA, Chen B, Brehar FM, Dragomir MP, et al. Editing and chemical modifications on non-coding RNAs in cancer: a new tale with clinical significance. Int J Mol Sci. 2021;22:581. doi: 10.3390/ijms22020581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Ding P, Liu P, Wu H, Yang P, Tian Y, Zhao Q. Functional properties of circular RNAs and research progress in gastric cancer. Front Oncol. 2022;12:954637. doi: 10.3389/fonc.2022.954637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Wu H, Zheng X, Liu Y, Shen J, Ye M, Zhang Y. Hsa_circRNA_102682 is closely related to lipid metabolism in gestational diabetes mellitus. Gynecol Endocrinol. 2022;38:50–54. doi: 10.1080/09513590.2021.1991911. [DOI] [PubMed] [Google Scholar]
- 19.Fernández-Tussy P, Ruz-Maldonado I, Fernández-Hernando C. MicroRNAs and circular RNAs in lipoprotein metabolism. Curr Atheroscler Rep. 2021;23:33. doi: 10.1007/s11883-021-00934-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Yu G, Yang Z, Peng T, Lv Y. Circular RNAs: rising stars in lipid metabolism and lipid disorders. J Cell Physiol. 2021;236:4797–4806. doi: 10.1002/jcp.30200. [DOI] [PubMed] [Google Scholar]
- 21.Li A, Sun Y, Drummer C, 4th, Lu Y, Yu D, Zhou Y, et al. Increasing upstream chromatin long-range interactions may favor induction of circular RNAs in LysoPC-activated human aortic endothelial cells. Front Physiol. 2019;10:433. doi: 10.3389/fphys.2019.00433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ye J, Li J, Zhao P. Roles of ncRNAs as ceRNAs in gastric cancer. Genes (Basel) 2021;12:1036. doi: 10.3390/genes12071036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Qian CJ, Tong YY, Wang YC, Teng XS, Yao J. Circ_0001093 promotes glutamine metabolism and cancer progression of esophageal squamous cell carcinoma by targeting miR-579-3p/glutaminase axis. J Bioenerg Biomembr. 2022;54(2):119–134. doi: 10.1007/s10863-022-09935-6. [DOI] [PubMed] [Google Scholar]
- 24.Quintavalle C, Meyer-Schaller N, Roessler S, Calabrese D, Marone R, Riedl T, et al. miR-579-3p controls hepatocellular carcinoma formation by regulating the phosphoinositide 3-kinase-protein kinase B pathway in chronically inflamed liver. Hepatol Commun. 2022;6(6):1467–1481. doi: 10.1002/hep4.1894. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ai J, Tan G, Li W, Liu H, Li T, Zhang G, et al. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579–3p/SIRT1/SSRP1 axis. Cell Biol Toxicol. 2022 doi: 10.1007/s10565-022-09738-w. [DOI] [PubMed] [Google Scholar]
- 26.Xu J, Xu W, Yang X, Liu Z, Sun Q. LncRNA HCG11/miR-579-3p/MDM2 axis modulates malignant biological properties in pancreatic carcinoma via Notch/Hes1 signaling pathway. Aging (Albany NY). 2021;13(12):16471–16484. doi: 10.18632/aging.203167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Qin Y, Zhang Y, Tang Q, Jin L, Chen Y. SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 2017;49:138–148. doi: 10.1093/abbs/gmw127. [DOI] [PubMed] [Google Scholar]
- 28.Hu B, Xiao F. Circular RNA F-circEA-2a expression is increased in gastric adenocarcinoma and inhibits the transition from premature microRNA-3940-5p to mature microRNA-3940-5p. Bioengineered. 2022;13:7011–7019. doi: 10.1080/21655979.2022.2038935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Mansoury F, Babaei N, Abdi S, Entezari M, Doosti A. Changes in NOTCH1 gene and its regulatory circRNA, hsa_circ_0005986 expression pattern in human gastric adenocarcinoma and human normal fibroblast cell line following the exposure to extremely low frequency magnetic field. Electromagn Biol Med. 2021;40:375–383. doi: 10.1080/15368378.2021.1891092. [DOI] [PubMed] [Google Scholar]
- 30.Wang C, Liu WR, Tan S, Zhou JK, Xu X, Ming Y, et al. Characterization of distinct circular RNA signatures in solid tumors. Mol Cancer. 2022;21(1):63. doi: 10.1186/s12943-022-01546-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Yang Y, Kang W, Yuan Y, Duan C, Chen W, Yu C. circ-0007707/miR-429/PDGFD pathway regulates the progression of gastric cancer by modulating the immune-gene signature. J Oncol. 2022;2022:2214686. doi: 10.1155/2022/2214686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism: New functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874:188394. doi: 10.1016/j.bbcan.2020.188394. [DOI] [PubMed] [Google Scholar]
- 33.Chua NK, Coates HW, Brown AJ. Squalene monooxygenase: a journey to the heart of cholesterol synthesis. Prog Lipid Res. 2020;79:101033. doi: 10.1016/j.plipres.2020.101033. [DOI] [PubMed] [Google Scholar]
- 34.You W, Ke J, Chen Y, Cai Z, Huang ZP, Hu P, et al. SQLE, a key enzyme in cholesterol metabolism, correlates with tumor immune infiltration and immunotherapy outcome of pancreatic adenocarcinoma. Front Immunol. 2022;13:864244. doi: 10.3389/fimmu.2022.864244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Li C, Wang Y, Liu D, Wong CC, Coker OO, Zhang X, et al. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut. 2022 doi: 10.1136/gutjnl-2021-325851. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S, et al. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2021;12:5066. doi: 10.1038/s41467-021-25325-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Nagaraja R, Olaharski A, Narayanaswamy R, Mahoney C, Pirman D, Gross S, et al. Preclinical toxicology profile of squalene epoxidase inhibitors. Toxicol Appl Pharmacol. 2020;401:115103. doi: 10.1016/j.taap.2020.115103. [DOI] [PubMed] [Google Scholar]
- 38.Xu XH, Shao SL, Guo D, Ge LN, Wang Z, Liu P, et al. Roles of microRNAs and exosomes in Helicobacter pylori associated gastric cancer. Mol Biol Rep. 2023;50(1):889–897. doi: 10.1007/s11033-022-08073-x. [DOI] [PubMed] [Google Scholar]
- 39.Sänger L, Bender J, Rostowski K, Golbik R, Lilie H, Schmidt C, et al. Alternatively spliced isoforms of AUF1 regulate a miRNA-mRNA interaction differentially through their YGG motif. RNA Biol. 2021;18:843–853. doi: 10.1080/15476286.2020.1822637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Qi X, Chen X, Zhao Y, Chen J, Niu B, Shen B. Prognostic roles of ceRNA network-based signatures in gastrointestinal cancers. Front Oncol. 2022;12:921194. doi: 10.3389/fonc.2022.921194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Wang S, Dong L, Ma L, Yang S, Zheng Y, Zhang J, et al. SQLE facilitates the pancreatic cancer progression via the lncRNA-TTN-AS1/miR-133b/SQLE axis. J Cell Mol Med. 2022;26(13):3636–3647. doi: 10.1111/jcmm.17347. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.